The first new treatment for Alzheimer’s disease for nearly 20 years has been approved by regulators in the United States, paving the way for its use in the UK.
Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms.
Charities have welcomed the news of a new therapy for the condition.
But scientists are divided over its potential impact because of uncertainty over the trial results.
Please subscribe HERE http://bit.ly/1rbfUog
#BBCNews
MILANO (ITALPRESS) – Aveva promesso un cambio di passo per l’Isola e quasi a metà legislatura, l’obiettivo sembra essere compiuto.…
As Donald Trump’s list of appointments becomes longer and more controversial, there’s one area that seems set for drastic change:…
In this episode of Path to the Presidency, the BBC’s Sumi Somaskanda and Caitríona Perry are joined by digital reporter…
In this episode of Path to the Presidency, the BBC’s Sumi Somaskanda and Caitríona Perry are joined by digital reporter…